Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PARP1 inhibitor IMP1734 enters human trials for advanced cancers

NCT ID NCT06253130

Disease control Sponsor: Eikon Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will take the drug by mouth, and researchers will monitor side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IMP1734 (a PARP1 inhibitor drug)
What this could lead to
If it works, this could point toward a new treatment option for certain advanced cancers like breast, ovarian, or prostate cancer.
What could go wrong
This is an early phase 1/2 trial with a small number of participants, so it may not show strong anti-tumor effects. Side effects are possible, and the drug may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria * Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+, * HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease * mCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy * Age ≥ 18 years at the time of informed consent * Eastern Cooperative Oncology Group (ECOG) performance status ≤1 * Adequate organ function * Life expectancy ≥ 12 weeks * Should have evaluable disease as defined by RECIST1.1 and/or CA125 or PSA * Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of IMP1734 * deleterious or suspected deleterious germline or somatic mutations of select HRR genes * up to 1 prior line of PARP inhibitor containing treatment Key Exclusion Criteria: * Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734 * Have received prior PARP1 selective inhibitors * Mean resting QTcF \> 470 ms or QTcF \< 340 ms * Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. * Infections \- An active hepatitis B/C infection * Any known predisposition to bleeding * Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer castration-resistant prostate carcinoma fallopian tube cancer metastatic prostate carcinoma neoplasm ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    47 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Advent Health Research Institute

    RECRUITING

    Celebration, Florida, 34747, United States

  • CHA Bundang Medical Center, CHA University

    RECRUITING

    Seongnam-si, Gyeonggi-do, 13496, South Korea

  • CLCC François Baclesse

    RECRUITING

    Caen, 14075, France

  • Cayuga Medical Center

    WITHDRAWN

    Ithaca, New York, 14850, United States

  • Chongqing University Cancer Hospital

    RECRUITING

    Chongqing, 400044, China

  • Clínica Universidad de Navarra - Hospital

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Cross Cancer Institute

    RECRUITING

    Edmonton, Alberta, T6G 1Z2, Canada

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, 200120, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, 350000, China

  • Fundacion MD Anderson Cancer Center

    RECRUITING

    Madrid, 28033, Spain

  • Gachon University - Gil Medical Center

    RECRUITING

    Incheon, Namdong-gu, 21565, South Korea

  • Gold Coast Private Hospital

    NOT_YET_RECRUITING

    Southport, Queensland, 4125, Australia

  • Henry Ford Health

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Hoag Health Center Irvine

    WITHDRAWN

    Irvine, California, 92618, United States

  • Hospices Civils de Lyon - CHU Lyon Sud

    RECRUITING

    Pierre-Bénite, Rhone, 69310, France

  • Hospital Clinico San Carlos

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • Hospital Clinico Universitario de Valencia - INCLIVA

    RECRUITING

    Valencia, 46010, Spain

  • Hospital Universitari Parc Taulí

    RECRUITING

    Sabadell, Barcelona, 08208, Spain

  • Hospital del Mar

    RECRUITING

    Barcelona, 08003, Spain

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • John Theurer Cancer Center

    WITHDRAWN

    Hackensack, New Jersey, 07601, United States

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Lifespan Cancer Institute

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • Macquarie University

    RECRUITING

    Sydney, Queensland, 2109, Australia

  • Mater Cancer Care Centre, Mater Misericordiae Limited

    RECRUITING

    South Brisbane, Queensland, 4101, Australia

  • Medical University of South Carolina (MUSC) - Hollings CC

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • Peninsula and south eastern haematology and oncology group

    RECRUITING

    Frankston, Victoria, 3199, Australia

  • Princess Alexandra Hospital

    RECRUITING

    Woolloongabba, Queensland, 4102, Australia

  • Princess Margaret Cancer Centre-University Health Network

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Righospitalet

    RECRUITING

    Copenhagen, 2100, Denmark

  • START - South Texas Accelerated Research Therapeutics

    WITHDRAWN

    San Antonio, Texas, 78229, United States

  • START Madrid Fundación Jiménez Díaz

    RECRUITING

    Madrid, 28040, Spain

  • START Mountain Region

    WITHDRAWN

    West Valley City, Utah, 84119, United States

  • START-CIOCC HM Sanchinarro Hospital

    RECRUITING

    Madrid, 28050, Spain

  • Sarah Cannon Research Institue Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute Health One

    RECRUITING

    Denver, Colorado, 80218, United States

  • Scientia Clinical Research Ltd

    ACTIVE_NOT_RECRUITING

    Randwick, New South Wales, 2031, Australia

  • Severance Hospital, Yonsei University Health System

    RECRUITING

    Seoul, 03722, South Korea

  • Shandong Cancer Hospital

    RECRUITING

    Jinan, Shandong, 250117, China

  • Sharp Memorial Hospital

    WITHDRAWN

    San Diego, California, 92123, United States

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310016, China

  • Smilow Cancer Hospital at Yale New Haven

    RECRUITING

    New Haven, Connecticut, 06511, United States

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

  • Sunnybrook Research Institute

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • Sylvester Comprehensive Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

  • The Fourth Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, 050011, China

  • The University of Arizona Cancer Center

    RECRUITING

    Tucson, Arizona, 85719, United States

  • Universidad De Sevilla - Hospital Universitario Virgen Macarena

    RECRUITING

    Seville, 41009, Spain

  • University California Irvine

    WITHDRAWN

    Irvine, California, 92868, United States

  • University of Arkansas Winthrop P. Rockefeller Cancer Institute

    RECRUITING

    Little Rock, Arkansas, 72205, United States

  • University of California San Francisco (UCSF)

    WITHDRAWN

    San Francisco, California, 94158, United States

  • University of Michigan Rogel Cancer Center

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • University of Minnesota-Clinical Research Unit

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Vall d'Hebron Institute of Oncology

    RECRUITING

    Barcelona, 08035, Spain

  • Washington University - Siteman Cancer Center

    WITHDRAWN

    St Louis, Missouri, 63110, United States

  • West Cancer Center & Research Institute

    RECRUITING

    Germantown, Tennessee, 38138, United States

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.